Evidence map›Paper›PMID 40836692›Full record

ReviewJournal of Parkinson's disease2026

Do we need drugs for psychiatric symptoms specifically for Parkinson's disease?

Kelly A Mills, Gregory M Pontone

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kelly A MillsDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-4302-1501
Gregory M PontoneDepartment of Neurology, Norman Fixel Institute, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-9540-6913

Funding

Visual hallucinations and memory impairment in Parkinson's Disease: The role of hippocampal networksR01MH123552 · NIMH · JOHNS HOPKINS UNIVERSITY · PI BAKKER, ARNOLD, PONTONE, GREGORY MICHAEL · 2021 to 2025
$3.1M
The role of cortical nicotinic receptors in pathological brain oscillations in Parkinson's disease cognitive impairmentR21NS128391 · NINDS · JOHNS HOPKINS UNIVERSITY · PI MILLS, KELLY ALEXANDER · 2023 to 2024
$450k
NIMH NIH HHS R01 MH123552NINDS NIH HHS R21 NS128391
6 · The paper itself

Abstract

Although the need for better medications for the treatment of psychiatric symptoms in people with Parkinson's disease (PWP) is not disputed, the approach and targets for these medications needs further attention. Psychiatric symptoms occur at higher prevalence in PWP-many start in the prodromal phase of the disease-and have complex associations and interactions with the motor symptoms and their treatments, begging the question of whether they may be mechanistically connected. In this manuscript, we review the current evidence for pharmacologic treatments of psychiatric symptoms in PWP and explore the potential next steps needed to develop new medications for psychiatric symptoms in PD.

Indexed as

Mental DisordersParkinson DiseaseHumansanxietyapathydepressionimpulse controlParkinson's diseasepsychosis

Identifiers

PMID40836692
PMCPMC13435215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.